However, treatment in the metastatic setting is typically palliative; the American Society of Clinical Oncology guidelines did not find the demonstrable benefit of G-CSF prophylaxis in patients with metastatic disease, which is consistent with the small number of patients who received G-CSF prophylaxis in the palliative intent subgroup of the present study [6]. This evidence concerns the gene CSF3 and metastatic neoplasm.